Breztri Approved in the U.S. for Asthma as First and Only Triple Therapy for Patients 12 Years of Age and Older
April 29, 2026
April 29, 2026
WILMINGTON, Delaware, April 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
Approval based on KALOS and LOGOS Phase III trials demonstrating statistically
significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual thera . . .
* * *
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
Approval based on KALOS and LOGOS Phase III trials demonstrating statistically
significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual thera . . .